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Summary The level of expression of keratinocyte growth factor (KGF) mRNA has been measured in human breast cell lines, purified
populations of epithelial cells, myoepithelial cells and fibroblasts from reduction mammoplasty tissue and a panel of 42 breast cancers and
30 non-malignant human breast tissues using a semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR) procedure. We
found similar levels of KGF mRNA in malignant and non-malignant breast tissues. The study of the amount of KGF mRNA in breast cell lines
and purified populations of cells revealed that fibroblasts are the predominant source of KGF with malignant and non-malignant epithelial cells
containing very low levels of KGF mRNA. We have examined thedistribution offibroblastgrowth factor receptor(FGFR)-2-lllb, which is a high-
affinity receptor for KGF and find that it is present on malignant and non-malignant epithelial cells. The level of FGFR-2-lllb present on breast
cancer cell lines was sufficient for KGF stimulation of breast cancer cell proliferation. Other members ofthefibroblastgrowth factorfamily have
been either not expressed in the human breast (FGF3, FGF4) or have been found at much reduced levels in breast cancer (FGF1, FGF2) and
this is the first member of the family to potentially influence the progression of breast cancerthrough stimulation of cell division.
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Fibroblast growth factors (FGFs) comprise a family of nine
polypeptide mitogens including acidic FGF (FGF1), basic FGF
(FGF2), int-2 (FGF3), hst (FGF4), FGF5, FGF6 and keratinocyte
growth factor (KGF or FGF7) (Basilico and Moscatelli, 1992).
Two more recently identified members ofthe family are androgen-
induced growth factor (AIGF, FGF8) and glia-activating factor
(GAF, FGF9) (Tanaka et al, 1992; Miyamoto et al, 1993). KGF
differs from the other members by its high specificity for acti-
vating epithelial cells (Finch et al, 1989). It is expressed in cells of
mesenchymal origin such as fibroblasts and endothelial cells but
not in epithelial cells (Finch et al, 1989; Smola et al 1993). It
therefore seems likely that KGF stimulates epithelial cells in a
paracrine manner.
Fourgenes encoding high-affinity receptors forFGFs havebeen
described and the complexity of this gene family is enhanced by
extensive variation in splicing (Jaye etal, 1992). Each receptorhas
a similar structure ofthree extracellular immunoglobulin domains
that are involved in ligand binding, a transmembrane domain and
an intracellular split tyrosine kinase domain (Jaye et al, 1992).
KGF binds to a splice variant of FGFR-2 (Miki et al, 1991).
Alternative splicing of the carboxyl-terminal half of the third
immunoglobulin-like domain changes the ligand-binding proper-
ties of FGFR-2 with FGFR-2-IIIb binding to FGF1 and KGF
whereas FGFR-2-IIIc binds to FGF1 and FGF2 (Miki et al, 1992;
Yayon et al, 1992). These two isoforms of FGFR-2 appear to be
expressed in a mutually exclusive fashion in many cell systems.
Cells of mesenchymal origin express FGFR-2-HIc, whereas
epithelial cells express FGFR-2-IIIb (Pekonen et al, 1993;
Savagner et al, 1994).
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Several studies have examined the expression of FGFs in the
malignant and non-malignant breast. mRNA encoding FGF1,
FGF2, FGF5, FGF6, FGF7 and FGF9 has been detected in breast
cancer, with expression of FGF1 and FGF2 found in all breast
cancers whereas the others showed more restricted expression
(Penault-Llorca et al, 1995). Quantitative studies comparing
expression levels in malignant and non-malignant breast showed
that FGF1 and FGF2 are present in considerable quantities in the
non-malignant breast but their expression is greatly reduced in
malignant tissues (Bansal et al, 1995; Anandappa et al, 1994;
Luqmani et al, 1992). These results may indicate that FGF1 and
FGF2 have a role in maintaining the normal ducts. FGF2 has been
localized to the myoepithelial cells of the normal breast by
immunocytochemistry but could not be detected in normal or
malignant epithelial cells by this technique (Gomm et al, 1991).
High-affinity receptors for FGFs are found in breast cancer cells.
Amplification of the FGFR-J and FGFR-2 genes was found in
12.7% and 11.5% ofbreasttumours respectively and gene amplifi-
cation ofFGFR-4 was found in 10% ofbreast cancers (Adnane et
al 1991, Jaakkola et al, 1993). Elevated levels of FGFR mRNAs
were found in several breast cancer cell lines (Lehtola et al, 1992;
McLeskey et al 1994). The expression ofdifferent splice variants
of FGF receptors could also be important in breast cancer and a
high ratio of beta to alpha form expression of FGFR-1 has been
associated with a reduced disease-free survival in patients with
breast cancer (Luqmani et al 1995).
In this study, we have addressed the issue ofwhether KGF has a
role in the human breast and the development of breast cancer.
KGF is an androgen-induced stromal growth factor that can
stimulate epithelial growth and morphogenesis in the developing
prostate and seminal vesicle (Yan et al, 1992; Alarid et al, 1994).
KGF has also been shown to be a progestomedin in the
endometrium of primates (Koji et al, 1994). Its role in the
mammary gland, another steroidhormone-dependent tissue, is less
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Table 1 Details of patients studied
Characteristic Number of patients Patients(%)
Total number of patients 42
Age range 29-76
Mean age 65
Menopausal status
Pre 11 30
Post 26 70
Not known 5
Clinical stage
T1/T2 28 90
T3/T4 4 10
Not known 10
Node status
Negative 18 60
Positive 12 40
Not known 12
ER status
Positive 9 60
Negative 6 40
Not known 27
Histological type
Infiltrating ductal 33 89
Infiltrating lobular 4 11
Not known 5
well defined. However, studies in mice have shown that KGF is a
mitogen forprimary cultures ofmammary epithelium (Imagawa et
al, 1994) and systemic administration ofKGF leads tohyperprolif-
eration ofthe mammary gland, giving the histological appearance
of fibrocystic disease (Yi et al, 1994). KGF has been linked to
human pancreatic cancer with 44% of pancreatic cancer samples
showing overexpression of KGF mRNA by Northem analysis
(Siddiqi et al, 1995). Our results indicate that KGF mRNA is
present at approximately the same levels in non-malignant and
malignant breast tissue, where it is expressed by stromal cells and
is able to stimulate epithelial cells. It may have a role in normal
mammary development and morphogenesis and, in contrast to
FGF1 and FGF2, is retained in malignant tissue where it could
potentially influence the growth ofbreast cancers.
MATERIALS AND METHODS
Reverse transcriptase was from Gibco-BRL (Paisley, UK), Taq
polymerase from Peninsula Laboratories (UK), DNA polymerase
klenow fragment and dNTPs from Pharmacia (Uppsala, Sweden).
RNAzol was from Biogenesis (Boumemouth, UK). [a-32P]dCTP
(3000 Ci mmol-1) andHybond N+ membranes andHyperfilm were
from Amersham (UK). All other reagents were obtained from
Sigma (Poole, UK) unless otherwise indicated and were of the
highest available grade.
Cell lines
Twelve human mammary cell lines were used in this study: two
breast cell lines ofnon-malignant origin, HBR-SV1.6.1 (epithelial)
and MCF1Oa (epithelial), and ten derived from cancer tissue;
T47D, ZR-75-1, SKBRII1, MDA-MB-231, MDA-MB-361,
MDA-MB-453, MDA-MB-157, BT20, PMC42 and MCF7. A
further two non-breast cell lines rat L6 myoblasts and MCR5 fetal
lung fibroblasts were also analysed forcomparison. Allbutthree of
these cell lines were cultured in RPMI-1640 mediumbuffered with
25 mm Hepes and supplemented with 10% fetal calf serum (FCS),
100 units ml-' penicillin, 100 jig ml-1 streptomycin and 2 mM L-
glutamine. The SKBR111 cells were grown in McCoy's SA
medium with the same supplements as above and the MCF1Oa
cells in a medium containing equal quantities ofDulbecco's modi-
fied eagle medium (DMEM) and Ham's nutrient mixture F-12
buffered with 15 mm Hepes with the following supplements:
10 gg ml-1 insulin, 1.4 nm hydrocortisone, 100 ng ml-l cholera
enterotoxin, 20 ng ml-1 epidermal growth factor, 5% horse serum,
2 mm glutamine, 100 units ml-' penicillin and 100jg mll strepto-
mycin. Primary cultures of breast fibroblasts were grown in
DMEM: Ham's F12 1:1 with 15 mM Hepes and 100 U ml-1
penicillin, 100 jg mi-I streptomycin, 5 jig ml- amphotericin B,
50 U mi- polymixin B, 10 jg ml- insulin, 10 ng ml-' EGF, 1 jg
ml- hydrocortisone, 10 jig ml- transferrin, 0.1 mm ethanolamine
and 5% FCS. Cells were harvested at about 80% confluence.
Preparation of pure populations of breast epithelial and
myoepithelial cells
Separated breast fibroblasts, epithelial and myoepithelial cells
were prepared from reduction mammoplasty specimens by
immunomagnetic separation using the method of Gomm et al
(1995). Mouse monoclonal antibodies to common acute
lymphoblastic leukaemia antigen (CALLA) (Sera-lab) and epithe-
lial membrane antigen (EMA) (Sera-lab) were bound to anti-
mouse and anti-rat antibody-coated beads respectively
(Dynabeads) overnight at 4°C and then washed four times with
cold medium. Breast organoids were prepared from reduction
mammoplasty tissue by a modification ofthe method of Stampfer
et al (1980). Single cell suspensions were prepared by digestion of
organoids in PBS containing trypsin-EDTA (0.05%/0.02%) and
0.4 mg ml- DNAase for 15 min at 37°C. Cells were washed three
times in medium andfilteredthrough56-jim gauze. The cells were
incubated with anti-CALLA- or anti-EMA-coated beads in a ratio
oftenbeads pertargetcell. Three separate incubations of 15 min at
4°C were performed to collect cells.
RT-PCR analysis of purified populations of breast cells
to assess their purity
Cellular RNA was extracted from the purified fractions ofcells by
the modified RNAzol procedure (Chomczynsky and Saatchi,
1987). RNA (2jg) was reverse transcribed using randomprimers.
cDNA was amplified using 1 unit of Taq polymerase in 100 jl
containing 67 mM Tris-HCl pH 8.8, 1.5 mm magnesium chloride,
16 mm ammonium sulphate, 0.45% Triton X-100, 200 jig ml-
gelatin, 200 jm-' dNTPs and 200 ng of each of the EMA or
CALLA primers, by 40 sequential cycles of denaturation at 95°C
for 1 min, annealing at 55°C for 1 min and extension at 72°C for
1 min (extended to 10 min for the final cycle). Aliquots (10 jil) of
the 40 cycle PCR products were electrophoresed on a 1% agarose
gelcontaining ethidiumbromide andbands were visualizedby UV
illumination.
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Figure 1 Southern blot of RT-PCR products for KGF and actin amplified
from malignant and non-malignant tissues. RNA (2 jg) from breast tissues
was used to make cDNA. KGF and actin PCR products were amplified from
aliquots ofthis cDNA. The products were run on 1.5% agarose gels, blotted
onto Hybond N+ membrane and 32P-labelled probes were used to identify and
quantify bands. Lanes 1-9 contain PCR products from breast cancer tissues,
lanes 10-11 contain PCR products from non-malignant breast tissues
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Figure 2 Expression of KGF mRNA in malignant and noi
breast tissues. Levels of expression were assessed from
densitometry. Results are expressed as the ratio of KGF-
Levels of KGF mRNA in non-malignant tissues; *, levels
in breast cancers
CC N N C N C N KGF
Figure 3 Expression of KGF protein in malignant and no
breast tissues. Tissue lysates of cancer (C) and non-malii
and a recombinant KGF protein were run on a 15% acryl;
blotted onto nitrocellulose. The blot was probed with a ral
antibody against KGF and anti-rabbit horseradish peroxic
were visualized using ECL reagents
Tissues
Breast tissue obtained at surgery was snap froz
liquid nitrogen. We collected cancer tissue from
details are given in Table 1, showing these to be
sentative cohort of breast cancer patients with
being pre/perimenopausal and 40% having oe:
positive carcinomas. Breast tissue adjacent to ca
benign conditions histologically confirmed to t
was also collected and is referred to as normal.
Oligonucleotides
Oligonucleotide primers were synthesized on aCyclone Plus DNA
Synthesizer (Milligan Bioresearch, MA, USA). The primers used
for the PCR were: for KGF, 5'-ATGGAAATCAGGACAGTGGC-
3' (sense) and 5'-CATAGGAAGAAAGTGGCCTG-3' (antisense);
for FGFR-2,5'-CTGGATGTTGTGGAGCGAT-3' (sense) and
5'-TGTAATCTCCTllTTCTCTT CCA-3' (antisense); for actin,
5'-CATCTCTTGCTCGAAGAAGTCCA-3' and 5'-ATCATGTTT-
GAGACCTTCAA-3'; for EMA, 5'-TCCGCTCCACCTCT-
CAAG-3' (sense) and 5'-CTCACAGCATTCTTCTCAGTAG-3'
(antisense); and for CALLA, 5'-TTGTAAGCAGCCTCAGCC-3'
(sense) and 5'-TTGTCCACClTTlCTCGG-3' (antisense). The
FGFR-2-IIIb PCR product was detected specifically by
hybridizing with the 32P-labelled intemal oligonucleotide 5'-
TGGGAACTATTTATCCCCG-3' (antisense).
Determination of KGF and FGFR-2-lllb mRNA by
RT-PCR amplification
Cellular RNA was extracted from pulverized frozen tissues using
the guanidiniumisothiocyanate method (Chirgwin et al, 1979)
and from the cell lines by the modified RNAzol procedure
(Chomczynsky and Saatchi, 1987). Reverse transcription and PCR
amplification was performed as described previously (Luqmani et
al, 1992). Briefly, 2 ,ug of RNA was reverse transcribed using
random primers and cDNA was amplified using 1 unit Taq poly-
merase in 100 gl containing 67 mm Tris-HCl pH 8.8, 1.5 mm
magnesium chloride, 16 mm ammonium sulphate, 0.45% Triton X-
100, 200 ,ug ml-' gelatin, 200 ,UM dNTPs and 200 ng ofeach ofthe
KGF orFGFR-2 and actin primers, by sequential cycles ofdenatu-
ration at 95°C for 1 min, annealing at 55°C (or 45°C for FGFR-2)
Sn-malignant human for 1 min and extension at 72°C for 1 min (extended to 10 min for
iSouthern blots by
-actin mRNA. 0, the final cycle). An aliquot was removed after 18 cycles for esti-
of KGF expression mation ofactin product and the reaction continued for a furtherten
cycles for estimation ofKGF and FGFR-2. Aliquots (10gl) ofthe
28 cycle and 18 cycle PCRproducts wereelectrophoresed on sepa-
rate 1% agarose gels and alkali blotted ovemight onto Hybond N+
membrane (Luqmani et al 1992).
-30kDa Hybridization was carried out as described by Church and
Gilbert (1984). Weinitially usedplasmids containing KGF oractin
-21.5kDa cDNA for hybridizations to verify identity and size of PCR
products. As single bands were seen, we subsequently used PCR
products (made using plasmid template) random primer labelled
(Feinberg and Vogelstein, 1983) with [32P]dCTP (5 x 108 to
in-malignant human 5 x 109c.p.m.jg-', 5 x 106 c.p.m. ml-'). In the case ofFGFR-2, the
imide gel and 32P-labelled intemal oligonucleotide 5'-TGGGAACTATTTATC-
bbit polyclonal CCCG-3' (antisense), which hybridizes to FGFR-2-IIIb but not to
Jase and bands FGFR-2-IIIc, was used to detect FGFR-2-IIIb. Washed blots were
exposed to photographic film for several hours and band intensi-
ties were quantified by densitometry. The values for KGF and
FGFR-2-Illlb were normalized by dividing the signal for KGF or
FGFR-2-IIlb by that for actin. Separate blots were normalized to
zen and stored in each other by using an arbitary sample that was present on every
42 patients whose run and every blot to correct for differences between experiments.
a typically repre-
30% of patients 3trogen receptor- Detection of KGF by western blotting ~strogen receptor-
arcinoma or from The tissues were lysed in PBS containing 1% NP40, 0.1% SDS,
be non-malignant 100jg ml-' phenylmethylsulphonyl fluoride (PMSF) and5 jg ml-1
aprotinin and then mixed with an equal volume of SDS-PAGE
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Figure 4 Purity of purified populations of epithelial and m!
from reduction mammoplasty tissue. RT-PCR was used to
encoding the epithelial cell marker EMA and the myoepith
CALLA from RNA extracted from populations of epithelial
cells purified from reduction mammoplasty tissue. PCR pr
on a 1.5% agarose gel containing ethidium bromide and b
by UV illumination. Lanes marked E contain the PCR prod
cells and lanes marked M contain the PCR product from n
KGF-actin ratio
0
Epithelial
Myoepithelial
Fibroblast
HBR-SV-161
MCF1Oa
MCF-7
T47D
ZR-75-1
MDA-MB-361
MDA-MB-453
MDA-MB-157
BT-20
SKBr3
PMC42
MCR5
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Figure 5 Expression of KGF mRNA in breast cell lines and purified
populations of breast cells. RNA (2 gg) from breast tissues was used to
make cDNA. KGF and actin PCR products were amplified from aliquots of
this cDNA. The products were run on 1.5% agarose gels, blotted onto
Hybond N+ membrane and probed by Southern blotting. Levels of
expression were assessed by densitometry. Results are expressed as the
ratio of KGF-actin mRNA. The first three columns represent levels of KGF
mRNA in populations of cells from reduction mammoplasty tissue, HBR-SV-
161 and MCF1Oa are non-malignant breast epithelial cell lines, MCF-7,
T47D, ZR-75-1, MDA-MB-361, MDA-MB-453, MDA-MB-157, BT-20, SKBR3
and PMC42 are breast cancer cell lines and MCR5 are fetal lung fibroblasts
sample buffer containing 2-mercaptoethanol. Aliquots of lysate
containing 40 gg of protein were electrophoresed through a 15%
polyacrylamide gel. The separated proteins were transferred onto
nitrocellulose membranes for 3 h at 200 mA. The blots were
blocked with 3% milk powder in phosphate-buffered saline
containing 0.1% Tween 20 (PBS-T) for 1 h, incubated with poly-
clonal rabbit anti-KGF (R & D) antibody for 1 h and finally
incubated for a further hour with an anti-rabbit IgG antibody
conjugated to horseradish peroxidase (Sigma). After five washes
with PBS-T, bands were visualized using the ECL method
(Amersham, UK).
Cell proliferation assay
Approximately 5000 MCF7 or MDA-MB-231 cells in CDM5
medium (DMEM/F-12 containing, 10 nM Hepes, 10 nM L-gluta-
mine, 100 U ml penicillin, 200 mg ml-1 streptomycin, 50 U ml-
polymixin B, 2.5 mg ml-1 amphotericin B, insulin 3 mg ml-1,
hydrocortisone 0.5 mg ml-1, oestradiol 1 nM, fetuin 20 mg ml-,
transferrin 25 mg ml-', phosphoethanolamine 0.1 mM, BSA
yoepithelial cells 0.01%, ascorbic acid 10 mg ml-' dibutyryl cAMP 10 nm, sodium
amplify sequences selenate 2.6 ng ml-1, triiodothyronine 10 nm, trace element mix
elial cell marker 1 mlml) were seeded into each well of96-well plates except for
aducts were run out theedge wells. Oneplate was seeded perday ofharvest. The cells
)ands were viewed were treated with varying concentrations of growth factor in
Juctfrom epithelial CDM5 medium in replicates of six. Cells were incubated for 0-11
niyoepithelial cells
days and the number of viable cells in each well was measured
using the sulphorhodamine (SRB) assay (Skehan et al, 1990).
Cells were lysed with 50% ice-coldTCA for I h, rinsed with water
five times and stained with 0.5% sulphorhodamine red for 1 h,
after which the cells were rinsed in 10 mm Tris-HCI pH 7.4 and
left to dry overnight. The dye was dissolved by adding 100 gl of
10 mM Tris-HCl pH 7.4 to each well and the optical density at 492
nm ofeach well was read using a spectrophotometer.
RESULTS
KGF mRNA expression in breast tissues
A panel of 72 human breast tissues including 42 breast cancers
and 30 samples ofnormal breast (Table 1) was subjected to a semi-
quantitative RT-PCR analysis to examine their expression of KGF
mRNA. Samples were removed after 18 and 28 cycles of amplifi-
cation, atwhich point actin and KGFPCRproducts had notreached
saturating levels. Samples were run on agarose gels, blotted onto
Hybond N+ membranes and products were detected by Southern
blotting. A scanning densitometer was used to quantify levels of
product. Figure 1 shows a typical example of results. Single PCR
products of 319 bp for actin and 290 bp for KGF were detected as
expected. The level of KGF mRNA in each sample was standard-
izedby expressing it as aratio with the ubiquitously expressed actin
product. Different gels were standardized by the inclusion of stan-
dard samples on each gel. Expression levels of the malignant and
non-malignant tissue samples are shown on Figure 2. Slightly
lower levels of KGF mRNA were found in the cancers that had a
mean of0.45 and a range of0.014-2.40 compared with non-malig-
nant tissues, which had a mean of 0.915 and a range of 0.03-3.92.
However, this difference was not statistically significant (P = 0.15).
We therefore conclude that approximately equal levels of KGF
mRNA are present in malignant and non-malignant breast.
KGF protein in breast tissues
The expression of KGF protein was assessed in 20 malignant and
non-malignant tissue samples using Western blotting and a repre-
sentative blot is shown in Figure 3. The antibody used is specific
to KGF and did not cross-react with FGF1 and FGF2 (data not
shown). A band of28 kDa, which we believe corresponds to KGF,
was seen in most of the samples. This is slightly larger than the
recombinant KGF loaded alongside because of glycosylation, as
reported previously (Finch et al, 1995). Similar results were seen
to those shown above for KGF mRNA expression in that KGF was
present at similar levels in both malignant and non-malignant
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Figure 6 Expression of FGFR-2-llJb in breast cell lines and purHied
populations of breast cells. RNA (2 9g) from breast tissues was used to make
cDNA. FGFR-2 and actin PCR products were amplified from aliqluots of this
cDNA. The products were run on 1.5% agarose gels, blotted onto Hybond
N+ membrane and probed by Southern blotting using 3uP-labelled intemal
oligonucleotides. Levels ofexpression were assessed bydensitometry.
Results are expressedi of FGFR-2-lalb bRe cillbactin mRNA. The
first three columns represent levels of KGF mRNA in populations of
cells from reduction mammoplasty tissue, HBR-SV-161 is a non-malignant
breast epithelial cell line, MCF-7, ZR-75-1 and MDA-MB-231 are breast
cancer cell lines
tissues, although expression levels varied quite widely between
samples. Therefore KGF mRNA is translated into protein in both
malignant and non-malignant tissues and is present at sufficiently
high levels to allow detection by Westernblotting.
KGF mRNA is predominantly expressed in stromal
fibroblasts
The breast cancer cell lines MCF7, ZR-75-1, MDA-MB-361,
MDA-MB-453, MDA-MB-157, BT-20, SKBRIII, PMC42 and the
non-malignant epithelial cell snes HBR-SV 161 and MCFlOa
were tested by semiquantitative RT-PCR for the expression of
KGF mRNA. Other non-breast cell lines (myoblasts and MRC5
fetal lung fibroblasts) were included in this assay as well as popu-
lations of epithelal cells, myoepithelial cells and fibroblasts
purified from reduction mammoplasty tissue. The purity of the
epitheral and myoepithelial cell populations was tested by RT-
PCRusingprimers forEMA, which is amarkerforepithelial cells,
andCALLA, which is amarkerformyoepithelial cells. The results
shown in Figure 4 show that the cell populations were very pure,
with EMA mRNA being detected only in epithelial cells and
CALLA mRNA being detected only in myoepithelial cells. We
find low levels of KGF mRNA in both non-malignant and malig-
nant breast epithelial cells and in myoepithelial cells (Figure 5).
Much higher levels of expression are seen in all the fibroblast
cell lines examined. Breast fibroblasts purified from reduction
mammoplasty material express high levels of KGF mRNA as do
MRC5 fetal lung fibroblasts and myoblasts. The low levels of
KGF mRNA found in breast epithelial cells may reflect the sensi-
tivity of RT-PCR linked to a Southern blotting detection and may
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Figure 7 Proliferative effect of KGF and EGF on breast cancer cell lines
MDA-MB-231 (A) and MCF-7 (B). An SRB assay was used to assess the
effect of KGF on epithelial cell growth. The optical density at 492 nm reflects
the number of cells present in each well. *, Cells treated with no additional
growth factor; 0, cells treated with 10 ng ml-' KGF; O, cells treated with
10ng ml-' EGF
not result in translation ofKGF. In this case, KGF will be made in
the stromal fibroblasts ofboth non-malignant and malignantbreast
tissues with neither malignant nor non-malignant epithelial cells
contributing significantly to KGF expression.
Receptors for KGF (FGFR-2-lIlb) are present on breast
cancer cell lines and on normal epithelial cells
KGF binds with high affinity the IIIb splice variant of FGFR-2
(Miki et al, 1992; Yayon et al, 1992). We used a similar semiquan-
titative RT-PCR assay to determine the amount of this receptor in
breast cell lines and purified populations of breast cells from
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reduction mammoplasty tissue. Amplification of cDNA samples
resulted in a single band of 342 bp, which could contain DNA
amplified from mRNA encoding either FGFR-2-IIIb or FGFR-2-
IIlc. FGFR-2-IIIb alone was detected by hybridization with a 32p_
labelled internal oligonucleotide that hybridized specifically to
this form and did not hybridize to the FGFR-2-IIIc isoform. The
results shown in Figure 6 indicate that breast fibroblasts do not
express this splice variant of FGFR-2. In contrast, the FGFR-2-
HIlb mRNA was seen in purified populations of epithelial and
myoepithelial cells. Myoepithelial cells contained more of the
receptor than epithelial cells in cell preparations from three reduc-
tion mammoplasties. The results obtained from breast cell lines
indicated that breast cancer cell lines also express FGFR-2-IIIb.
The level of expression in MDA-MB-231 breast cancer cells was
approximately the same as that seen in purified normal epithelial
cells and higher levels of expression were seen in the MCF7 and
ZR-75-1 breast cancer cell lines. Even higher receptor expression
was seen in the HBR-SV-161 cell line, which is derived from
SV40 transformed non-malignant epithelial cells. In a previous
study, we showed that FGFR-2-HIlb is present in the majority of
breast tumour tissues with 89% of tissues containing levels of
FGFR-2-III-b that were sufficiently high to be detected using
the same RT-PCR technique combined with Southern blotting
(Luqmani et al, 1996).
Proliferative effect of KGF on breast cancer cell lines
We wished to investigate whetherthe level ofFGFR-2-IIIb expres-
sion in breast cancercells was sufficient to elicit a growth response
after treatment with KGF. A SRB cell proliferation assay was
performed to assess the proliferative effect ofKGF compared with
epidermal growth factor (EGF) on the breast cancer cell lines
MCF7 and MDA-MB-231. The cells were seeded into 96-well
plates and grown in the serum-free medium CDM5 supplemented
with 10 ng mll EGF or 10 ng ml-1 KGF. Cells were harvested and
assayed on the same day and at four subsequent time points. As
seen in Figure 7, the growth ofboth cell lines was slightly stimu-
lated by KGF treatment but not to as great an extent as seen with
EGF treatment. The degree of growth stimulation by KGF was
lower in MDA-MB-231 cells than in MCF7 cells, consistent with
the lower expression of FGFR-2-IIIb in MDA-MB-231 cells. We
conclude that KGF present in breast cancer may be able to stimu-
late cell proliferation in cancer cells and may have a role in
promoting malignant progression.
DISCUSSION
In this study, we have examined the expression of KGF mRNA in
malignant and non-malignant human breast tissue. We find
slightly lower levels in malignant tissues than non-malignant
tissues but the difference in expression levels is not statistically
significant (P = 0.15) and KGF mRNA levels are similar in both
categories oftissue. An examination ofKGF mRNA expression in
breast cell lines and purified populations of cells from reduction
mammoplasty tissue showed that the stromal fibroblasts will be
the main source ofKGF in the normal tissue samples. The uncon-
trolled proliferation of epithelial cells seen in breast cancer may
lead to a higher ratio ofepithelial cells to fibroblasts in malignant
tissues and therefore to a higher proportion of epithelial cell
mRNA in the RNA prepared from malignant samples. In fact,
when the same panel of tissue samples was analysed for expres-
sion of FGFR-2-IIIc, which has been reported to be expressed
by fibroblasts but not by epithelial cells (Pekonen et al 1993,
Savagner et al 1994), we detected twice as much FGFR-2-IIlc in
normal tissues than malignant tissues (results not shown). This
implies that the normal tissue RNA is indeed enriched for fibro-
blast RNA compared with malignant samples. Thus the cellular
complement ofmalignant and non-malignant tissues may account
for the observed decrease in KGF mRNA in malignant tissues
rather than a decrease in KGF mRNA expression in stromal
fibroblasts. The presence of KGF mRNA in malignant samples
argues for fibroblasts surrounding tumour cells continuing to
express KGF. Further studies in our laboratory using in situ
hybridization to detect KGF mRNA have indeed foundexpression
in fibroblasts surrounding cancer cells (Roberts-Clarke et al,
unpublishedresults).
We find little evidence to support expression of KGF by the
breast cancer cells. Although small amounts of KGF mRNA are
detected by RT-PCR in breast cancer cell lines, this detection
method is very sensitive and we have no evidence that the
presence of such low levels ofmRNA leads to translation of KGF.
When RNA from the same cell lines was tested forthe presence of
FGFR-2-IIIc, which is expressed in mesenchymal cells, using a
similar protocol of RT-PCR followedby use ofSouthernblotting,
very low levels were detected. This may indicate that the sensi-
tivity of the method allows detection of aberrant transcript that
will not go on to be translated, or may indicate that the cell lines
have adapted during culture and are no longer fully epithelial in
nature. The slightly lower levels ofKGF mRNA detected in breast
cancer tissues also argues against breast cancer cells expressing
significant amounts of KGF.
The continuing presence of KGF in breast cancer is in marked
contrast to other members ofthe FGFfamily. FGF1 and FGF2 are
present at significant levels in thenon-malignant breast. However,
a large decrease in expression of these growth factors is seen in
most breast cancers (Luqmani et al, 1992; Anandappa et al, 1994;
Bansal etal, 1995). Low levels ofFGF2 in breast cancerhave been
linked to poor prognosis (Yiangou et al, 1996). FGF3 and FGF4
are not detected in either malignant or non-malignant breast and
althoughFGF5, 6,7 and 9 havebeen detected in breast cancercell
lines, no detailed data are available on their levels of expression
(Wilson et al, 1994; Penault-Llorca etal, 1995). Therefore KGF is
the first FGF described for which expression is retained at an
equivalent level following the onset of malignant breast disease.
KGF differs from FGF1 and FGF2 in being expressed in stromal
fibroblasts rather than epithelial cells, and this may contribute to
its continued expression in breast cancer tissues.
Breast cancer cells express the FGFR-2-IIIb splice variant,
which has been identified as areceptorfor KGF(Miki etal, 1992).
Ourstudy ofFGFR-2-IIIbexpression showed noreceptor in breast
fibroblasts, consistent with a paracrine role for KGF as seen in
different tissues (Finch et al, 1989). In contrast, FGFR-2-IIIb was
found in both normal epithelial and myoepithelial cells and in
breast cancer cell lines at approximately the same level, although
we saw some variation between different breast cancer cell lines.
A previous study has used RNAase protection to measure the
amount of FGFR-2 expression in breast cancer cell lines
(McLeskey et al, 1994). Our results agree with this study, which
also found higher expression in MCF7 cells than in ZR-75-1 and
MDA-MB-231 cells. A previous study has reported that FGFR-2
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mRNA was detectable by Northern analysis in only 4% of breast
tumours examined (Penault-Llorca etal, 1995). However, using an
RT-PCR-based method, FGFR-2 was detectable in 89% of breast
tumours (Luqmani et al, 1996). It is likely that FGFR-2 is present
in the majority ofbreastcancers but atfairly low levels. This raises
the issue of whether the observed low levels ofFGFR-2 are suffi-
cient to allow KGF stimulation. Our cell proliferation assays
revealed thatthe levels ofFGFR-2-IIIb found inbreast cancercells
are sufficient to promote KGF-stimulated cell division, although to
a lesser extent than EGF. The MCF7 breast cancer cell line, which
expresses a higher level of KGF receptor, was stimulated to a
greater extent than MDA-MB-231, cells implying that higher
receptor expression may lead to a greater proliferative response.
We have only examined one aspect oftheresponse ofbreastcancer
cells to KGF stimulation and KGF stimulation may have other
consequences such as changing cell motility or invasiveness,
which could affect the progression of breast cancer. We have
previously reported that there is no significant difference between
the level of FGFR-2-IIIb mRNA in non-malignant and malignant
breast tissues and that FGFR-2-IIIb is detectable in 89% ofbreast
cancer tissues (Luqmani et al, 1996). Thus, KGF produced by
breast fibroblasts will have no autocrine role but could potentially
act on breast epithelial cells in both the normal and malignant
breast by a paracrine stimulation.
Like other members of the FGF family, KGF binds to heparin-
sulphate proteoglycans and would normally bind tightly to the
basement membrane that separates the stroma where KGF is
synthesized from the epithelial cells, which have receptors that
recognize KGF. In invasive breast cancer the basement membrane
and myoepithelial cells are no longer present and itis possible that
KGF will have greater access to the malignant epithelial cells. If
this situation is true, KGFmightbe expected to stimulate epithelial
cells to a greater extent in breast cancer than the normal breast.
Further experimentation will be required to test this hypothesis,
perhaps by testing whether larger quantities of KGF are released
into conditioned medium from breast cancer tissues than from
normal breast tissues. KGF is able to stimulate proliferation of
breast cancer cells and may have additional effects on cell motility
or invasiveness. It has been reported that KGF expression in
fibroblasts is induced by serum growth factors and pro-inflamma-
tory cytokines (Brauchle et al, 1994). These findings suggest that
serum factors that are released upon haemorrhage and cytokines
released from polymorphonuclear leucocytes and macrophages
will induce KGF in vivo. Both ofthese mechanisms may be active
in promoting the expression of KGF in fibroblasts surrounding
breast cancers.
Laboratory studies point to the importance ofstromal cells in the
development and growth ofbreast cancer. Conditioned media from
human breast cancer-derived fibroblasts stimulate the growth of
breast cancer cells (van Roozendaal et al, 1992; Ryan et al, 1993;
Singer et al, 1995). Co-culture experiments in which breast cancer
cells and fibroblasts are separated by a microporous membrane
have shown that factors secreted by fibroblasts stimulate the
growth of breast cancer cells with reciprocal stimulation of fibro-
blast growth by the breast cancer cells (Hofland et al, 1995). The
growth factors involved in this phenomenon are not well character-
ized; however, their effect is additive with that ofinsulin, EGF and
even serum (Hofland et al, 1995). This suggests that factors
involved will be different to these. Insulin-like growth factor II
expression is increased in fibroblasts surrounding breast tumours
and is able to stimulate the growth ofbreast cancercells, making it
a possible candidate as a paracrine growth factor affecting breast
cancer progression. However, other growth factors such as KGF
may also be involved (Singer et al, 1995; Cullen et al, 1992).
KGF is the first member of the FGF family to be found at
similar levels in breastcancers andnon-malignant breast tissues. It
is expressed in stromal fibroblasts and is capable of stimulating
cell proliferation of breast cancer cells in which expression of
FGFR-2-IIIb appears to be retained. The loss of the basement
membrane and myoepithelial cells in invasive breast cancer may
lead to greater access of KGF to the breast cancer cells. These
results suggest that further studies may be worthwhile in order to
investigate a possible paracrine role for KGF in breast cancer.
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